头颈癌初诊时脑转移的发生率与预后
基于美国国家癌症数据库(NCDB)2010–2015年465,925例头颈癌患者,其中440例初诊时伴脑转移(BM)。BM最常见于鼻咽NOS(13.2%)和腮腺(10.9%),总体中位生存7.1个月;放疗和多药化疗者中位生存分别为8.4和11.7个月,一线免疫治疗未影响中位生存。
要点
- 头颈癌初诊脑转移发生率低,但鼻咽NOS和腮腺占比最高。
- 初诊脑转移患者总体中位生存仅7.1个月。
- 骨或肺转移是多因素分析中脑转移的预测因素。
核心结论
- NCDB数据可用于辅助头颈癌脑转移患者的监测与管理。
研究设计与样本
- 基于NCDB的回顾性队列研究,纳入2010–2015年465,925例头颈癌患者,其中14,583例初诊即有远处转移,440例伴脑转移。
主要发现
- 总体中位年龄62.0岁,脑转移最常见于鼻咽NOS(13.2%)和腮腺(10.9%)。
- 总体中位生存时间为7.1个月。
- 单因素分析中骨、肝或肺转移为脑转移预测因素,多因素分析中骨或肺转移为预测因素。
- 高危HPV状态与脑转移概率较低相关。
- 接受放疗和多药化疗者中位生存分别为8.4和11.7个月,一线免疫治疗未影响中位生存。
关键数值与推荐
- 大多数患者接受放疗(62.7%)和化疗(50.2%)。
- 淋巴结受累水平与脑转移之间未确定明确模式。
临床怎么用
- 对初诊头颈癌患者,尤其伴骨或肺转移者,应关注脑转移监测。
- 高危HPV状态可能提示脑转移风险较低。
局限性
- 证据等级为4级,为基于数据库的回顾性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Limited data is available on head and neck cancer (HNC) patients presenting with brain metastases (BM) at initial diagnosis. We sought to evaluate the incidence, management, and treatment outcomes of these patients using the National Cancer Database (NCDB). METHODS: We identified 465,925 patients diagnosed with HNC between 2010 and 2015 in the NCDB. 14,583 of these patients presented with metastatic disease to any site. 440 of these patients had BM at the time of initial diagnosis. Overall survival was compared using the Kaplan-Meier method. Cox proportional hazard modeling, propensity score matching, and subgroup analyses were performed. RESULTS: The median age overall was 62.0 years. Nasopharynx NOS (13.2%) and Parotid Gland (10.9%) were the most common anatomical sites with the highest frequency of BM. The overall median survival time was 7.1 months. Predictors for the presence of BM included distant metastasis to the bone, liver, or lung on univariate analysis, and bone or lung on multivariate analysis. High-risk Human Papilloma Virus status was associated with a lower chance of BM. No pattern was determined when comparing lymph node level involvement and BM. The median survival for patients receiving radiation therapy and multi-agent chemotherapy was 8.4 and 11.7 months, respectively. Immunotherapy administered as first course therapy did not influence median survival. Most patients received radiation (62.7%) therapy and chemotherapy (50.2%). CONCLUSIONS: The data extracted and analyzed from the NCDB should work to aid in the surveillance and management of BM in patients with HNC. LEVEL OF EVIDENCE: 4 Laryngoscope, 131:E2543-E2552, 2021.
引用
- Messing I, Goyal S, Sherman JH, et al. Incidence and Prognosis of Brain Metastases in Head and Neck Cancer Patients at Diagnosis. Laryngoscope. 2021. PMID: 33599979. doi:10.1002/lary.29448
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。